Cenra Inc. (3716) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Cenra Inc. TWD 36.63, price TWD 33.95, upside +7.9%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cenra Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.
Show more
Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It provides CDMO services for internal and external partners; oral solids, injectables, specialty formulations, and APIs, supported by process development, scale-up, and regulatory support; oral solids, injectables, specialty formulations, and high-purity active pharmaceutical ingredients (APIs), supported by process development, scale-up, and regulatory support; distribution, and marketing for prescription drugs, OTC products, health supplements, personal care products, and medical devices;home care, caregiver training, and consulting for elderly support; develops and manufactures veterinary pharmaceuticals, and animal health products for livestock and companion animals and offers CDMO services for animal health partners. Cenra Inc. was founded in 2024 and is headquartered in Taipei, Taiwan.
Stock analysis
Cenra Inc. (3716) currently trades at 33.95 TWD, while our model-based Fair Value estimate is 36.63 TWD, implying the stock looks roughly 7.3% fairly valued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 41.24 TWD per share, and 17 of the 24 models we run sit above the 33.95 TWD price.
Bear case: the Dividend Discount group reads lowest at 7.75 TWD, and 7 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 26.06 TWD (bear) to 45.81 TWD (bull), the price of 33.95 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Cenra Inc. reported revenue of 8.6B TWD in FY2025 versus 7.9B TWD in FY2021, a compound +1.9%/yr. Reported net income was 300M TWD in FY2025, compounding −12.7%/yr from FY2021.
Key figures
Market cap 5.0B TWD (≈ $156M) · P/E ratio 8.9 · P/S ratio 0.31 · EPS (TTM) 3.83 TWD · Dividend yield 3.0% · Net margin 3.5% · Return on equity 4.8% · Return on assets (EBIT) 2.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 10% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 8%, 3716 screens richer than that median.
Fair Value models
Bear 26.06 TWDFair Value 36.63 TWDBull 45.81 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (2.08 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−3.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.4%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−7.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.0%
Dividend (yield on the price)3.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 5%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +7.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Top 25%
Fair Value upside+8% · Above median
Profitability
Return on equity (TTM)5% · Below median
Return on assets3% · Above median
Net margin (TTM)4% · Top 25%
Operating margin (TTM)9% · Top 25%
Growth and dividend
Revenue growth−1% · Below median
Dividend yield (TTM)3.0% · Above median
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cenra Inc. Fair Value". https://www.fairvalue-calculator.com/stock/3716
Frequently asked questions
Is Cenra Inc. (3716) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 36.63 TWD versus a price of 33.95 TWD, about +8% upside (fairly valued).
What is the fair value of 3716?
Our model-based fair value for Cenra Inc. is 36.63 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 33.95 TWD.
What is the quality score of 3716?
Cenra Inc. has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cenra Inc. (3716)?
Our model-based price target is the fair value of 36.63 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 26.06 TWD, optimistic scenario 45.81 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Cenra Inc. stock forecast for 2026?
Our models put fair value at 36.63 TWD, about +8% upside versus a price of 33.95 TWD (fairly valued). Cautious scenario 26.06 TWD, optimistic scenario 45.81 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Cenra Inc. (3716)?
Cenra Inc. reported trailing-twelve-month revenue of about 8.5B TWD (latest available figure, as of Sep 24, 2026).
Does Cenra Inc. pay a dividend?
Cenra Inc. currently shows a dividend yield of about 2.96% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Cenra Inc. (3716)?
For today's price to be fair in a discounted-cash-flow model, Cenra Inc. would have to grow free cash flow by +9.1 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +1.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 3716 use?
Our models discount Cenra Inc. at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cenra Inc. that is +9.1 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Cenra Inc. (3716) delivered so far?
Over the past 4 years revenue at Cenra Inc. grew +1.9 % a year. The price currently implies +9.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cenra Inc. (3716) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Cenra Inc. (+9.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cenra Inc. (3716)?
The free-cash-flow yield on the price is 10.66 %: that much free cash flow Cenra Inc. produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cenra Inc. (3716)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cenra Inc. it is 36.63 TWD per share (as of Sep 24, 2026), against a price of 33.95 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Cenra Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 3716 trades below its calculated fair value: price 33.95 TWD, fair value 36.63 TWD, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3716?
No. The price is what the market pays today (33.95 TWD); the fair value is what the company's own numbers justify (36.63 TWD). For Cenra Inc. the two are 2.68 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Cenra Inc. worth?
The market values Cenra Inc. at about 5.0B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 33.95 TWD; our models calculate a fair value of 36.63 TWD per share.
What do the bullish and bearish scenarios say about 3716?
Our models span a range for Cenra Inc.: cautious scenario 26.06 TWD, base 36.63 TWD, optimistic 45.81 TWD per share (as of Sep 24, 2026, price 33.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 3716?
Cenra Inc. trades at a price-to-earnings ratio of 8.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 36.63 TWD is built from several models across several years. Other multiples: P/B 0.7, P/S 0.6, EV/EBITDA 5.6.
How solid is the balance sheet of Cenra Inc. (3716)?
Balance-sheet figures for Cenra Inc. (as of Sep 24, 2026): return on equity 4.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 3716 from its 52-week high?
Cenra Inc. trades at 33.95 TWD, about 7% below its 52-week high of 36.70 TWD and 10% above the low of 30.73 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 36.63 TWD is for.
Which stocks are comparable to Cenra Inc.?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cenra Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 33.95 TWD, calculated fair value 36.63 TWD (+8%), Quality Score 60/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3716 calculated?
We run Cenra Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 36.63 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Cenra Inc. currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cenra Inc. (3716)?
The closing price on Sep 24, 2026 was 33.95 TWD. Our model-based fair value is 36.63 TWD, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cenra Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Cenra Inc.
How large is the market capitalisation of Cenra Inc. (3716)?
The market capitalisation of Cenra Inc. is 5.0B TWD (≈ $156M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cenra Inc. (3716)?
The price-to-sales ratio of Cenra Inc. is 0.31 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cenra Inc. (3716)?
Earnings per share at Cenra Inc. are 3.83 TWD (price ÷ EPS = P/E 8.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cenra Inc. (3716)?
The dividend yield of Cenra Inc. is 3.0% (payout 26.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cenra Inc. (3716)?
The net margin of Cenra Inc. is 3.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cenra Inc. (3716)?
The return on equity (ROE) of Cenra Inc. is 4.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cenra Inc. (3716)?
On an EBIT basis the return on assets of Cenra Inc. is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cenra Inc. (3716)?
The operating margin of Cenra Inc. is 9.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cenra Inc. (3716)?
Revenue at Cenra Inc. is growing −1.2% versus a year earlier (3y avg +0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cenra Inc. (3716)?
Earnings per share at Cenra Inc. are growing +68.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Cenra Inc. (3716) carry?
The net debt of Cenra Inc. is 1.9B TWD (fiscal year 2025, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cenra Inc. in the live analysis
One click puts Cenra Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
